Synthetic, non-hormonal antipyretic oral paste useful in the management of inflammatory conditions.
For Veterinary Use Only
Each syringe contains 20 g phenylbutazone.
Each 3 mL marking on the plunger contains Phenylbutazone: 1 g.
ButaVet® Phenylbutazone Paste is a synthetic, non-hormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound’s anti-inflammatory properties. Chemically, Phenylbutazone Paste is 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione. It is pyrazolone derivative, entirely unrelated to steroid hormones.
For the relief of inflammatory conditions associated with the musculosketal systems in horses.
Use with caution in patients who have a history of drug allergy.
Not for use in horses intended for food.
Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, though rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase therapy and at intervals of two weeks thereafter. Any significant fall in the total white blood cell count, relative decreases in granulocytes, or black or tarry stools should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter-measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.
Orally – 1 to 2 g of phenylbutazone per 500 lb. of body weight daily. Do not exceed 4 g daily.
When administering ButaVet® Phenylbutazone Paste, the oral cavity should be empty. Deposit paste on the back of tongue by depressing plunger that has been previously set to deliver the correct dose.
Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response. Response to ButaVet® Phenylbutazone Paste therapy is prompt, usually occurring within 24 hours. If no significant clinical effect is evident after five days, re-evaluate diagnosis and therapeutic approach.
Many chronic conditions will respond to ButaVet® Phenylbutazone Paste therapy, but discontinuance of treatment may result in recurrence of symptoms.
Store at 15°-30°C (59°-86°F)
Syringes containing 20 g Phenylbutazone.
Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Manufactured by: Med-Pharmex, Inc.
Pomona, CA 91767-1861
Revised June 2012
Net Volume 60 mL